Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Halofantrine Hydrochloride

FDA-approved product (tablet, oral), marketed as Halfan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Halofantrine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antimalarials
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BX01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Halofantrine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Halofantrine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults

    NCT01155037 · start 2010-03

    Registered record
    Registry ID
    NCT01155037
    Conditions
    HIV Infection
    Interventions
    Adjuvanted vaccine against H1N1 influenza virus (GSK); Adjuvanted vaccine against H1N1 influenza virus (GSK); Adjuvanted vaccine against H1N1 influenza virus (GSK)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03
    Completion
    2012-04
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionAdjuvanted vaccine against H1N1 influenza virus (GSK); Adjuvanted vaccine against H1N1 influenza virus (GSK); Adjuvanted vaccine against H1N1 influenza virus (GSK)
    PhasePhase 2
    Registry statusCompleted

  • Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients

    NCT01022905 · start 2009-11

    Registered record
    Registry ID
    NCT01022905
    Conditions
    HIV Infection; Rheumatic Disease; Cancer; Transplant; Pediatrics
    Interventions
    Adjuvanted influenza A(H1N1) vaccines
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-02
    Enrolment
    1,141

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Rheumatic Disease; Cancer; Transplant +1 more
    InterventionAdjuvanted influenza A(H1N1) vaccines
    PhasePhase 4
    Registry statusCompleted

  • Paxil CR Bioequivalence Study Brazil - Fed Administration

    NCT01339247 · start 2009-10-20

    Registered record
    Registry ID
    NCT01339247
    Conditions
    Depressive Disorder
    Interventions
    Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico; Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-10-20
    Completion
    2009-11-16
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder
    InterventionPaxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico; Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada
    PhasePhase 1
    Registry statusCompleted

  • Paxil CR Bioequivalence Study Brazil

    NCT01316926 · start 2009-09-09

    Registered record
    Registry ID
    NCT01316926
    Conditions
    Depressive Disorder
    Interventions
    Test formulation; Reference formulation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-09-09
    Completion
    2009-10-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder
    InterventionTest formulation; Reference formulation
    PhasePhase 1
    Registry statusCompleted

  • Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students

    NCT01861613 · start 2009-09

    Registered record
    Registry ID
    NCT01861613
    Conditions
    Hepatitis B; Immune Response; Seroprevalence
    Interventions
    HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    Not recorded
    Enrolment
    2,040

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; Immune Response; Seroprevalence
    InterventionHBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

    NCT00866619 · start 2009-03-27

    Registered record
    Registry ID
    NCT00866619
    Conditions
    Malaria
    Interventions
    Malaria Vaccine 257049; Meningococcal C Conjugate Vaccine; Cell-culture rabies vaccine; TritanrixHepB/Hib; Polio Sabin Oral Polio Vaccine (GSK)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-03-27
    Completion
    2014-01-31
    Enrolment
    15,459

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionMalaria Vaccine 257049; Meningococcal C Conjugate Vaccine; Cell-culture rabies vaccine; TritanrixHepB/Hib +1 more
    PhasePhase 3
    Registry statusCompleted

  • Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease

    NCT00815282 · start 2009-02

    Registered record
    Registry ID
    NCT00815282
    Conditions
    Juvenile Idiopathic Arthritis; Systemic Lupus Erythematosus; Juvenile Dermatomyositis
    Interventions
    Human papilloma virus vaccine (cervarix)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-02
    Completion
    2015-01
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJuvenile Idiopathic Arthritis; Systemic Lupus Erythematosus; Juvenile Dermatomyositis
    InterventionHuman papilloma virus vaccine (cervarix)
    PhasePhase 4
    Registry statusCompleted

  • The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

    NCT00827554 · start 2008-12

    Registered record
    Registry ID
    NCT00827554
    Conditions
    Hepatocellular Carcinoma
    Interventions
    LMWH; TACE
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2011-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionLMWH; TACE
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression

    NCT01907217 · start 2008-05

    Registered record
    Registry ID
    NCT01907217
    Conditions
    Depression
    Interventions
    ECT Mecta 5000M; Methohexitone; Suxamethonium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    2015-04
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionECT Mecta 5000M; Methohexitone; Suxamethonium
    PhasePhase 4
    Registry statusCompleted

  • Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

    NCT00490061 · start 2007-07

    Registered record
    Registry ID
    NCT00490061
    Conditions
    Head and Neck Cancer; Carcinoma, Squamous Cell; Head and Neck Cancers
    Interventions
    Lapatinib; Radiotherapy (radiation); G.E. Healthcare 1.5T MR, systems revision 12.0 M5; DCE-MRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-07
    Completion
    2016-06
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer; Carcinoma, Squamous Cell; Head and Neck Cancers
    InterventionLapatinib; Radiotherapy (radiation); G.E. Healthcare 1.5T MR, systems revision 12.0 M5; DCE-MRI
    PhasePhase 2
    Registry statusTerminated

  • Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

    NCT00426361 · start 2007-02-13

    Registered record
    Registry ID
    NCT00426361
    Conditions
    Infections, Papillomavirus
    Interventions
    Boostrix ® Polio; GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-02-13
    Completion
    2008-07-25
    Enrolment
    751

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Papillomavirus
    InterventionBoostrix ® Polio; GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)
    PhasePhase 3
    Registry statusCompleted

  • Use of N-Acetylcysteine During Liver Procurement

    NCT01394497 · start 2006-12

    Registered record
    Registry ID
    NCT01394497
    Conditions
    Liver Failure; Liver Failure, Acute; Liver Diseases; Carcinoma, Hepatocellular; Liver Neoplasms
    Interventions
    N-acetylcystein
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-12
    Completion
    2009-07
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Failure; Liver Failure, Acute; Liver Diseases; Carcinoma, Hepatocellular +1 more
    InterventionN-acetylcystein
    PhasePhase 2
    Registry statusCompleted

  • A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions

    NCT00864981 · start 2005-09

    Registered record
    Registry ID
    NCT00864981
    Conditions
    Depression
    Interventions
    Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.; WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-09
    Completion
    2005-10
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionBupropion HCI ER Tablets, 150 mg; EON Labs Inc.; WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
    PhasePhase 1
    Registry statusCompleted

  • Use of Sodium Stibogluconate as a Treatment for Leishmaniasis

    NCT00657618 · start 2004-10

    Registered record
    Registry ID
    NCT00657618
    Conditions
    Leishmaniasis
    Interventions
    Sodium Stibogluconate (SSG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2004-10
    Completion
    2015-04
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis
    InterventionSodium Stibogluconate (SSG)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions

    NCT00946387 · start 2004-09

    Registered record
    Registry ID
    NCT00946387
    Conditions
    Nausea; Vomiting
    Interventions
    Ondansetron HCl 24 mg Tablets (Sandoz, Inc.); Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-09
    Completion
    2004-09
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea; Vomiting
    InterventionOndansetron HCl 24 mg Tablets (Sandoz, Inc.); Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
    PhasePhase 1
    Registry statusCompleted